GMED in the 13F filings
Globus Medical Inc · CUSIP 379577208
- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 21 Jul 2025
- latest of these filings; the earliest 2 May 2025
- Managers listing it
- 13
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 9 listed it in both
- Shares listed
- 13,050,015
- combined, among listed positions
- Reported value
- $951m
- combined, at the quarter end
Among the 95 comparable managers: 9 buyers (opened or added shares) and 4 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing GMED in Q1 2025
13 of 13 holders
Largest increases and reductions, by shares
Increases
- Holocene Advisors LPnew position · 460,087 shares now+460,087
- Janus Henderson Group Ltdexisting position · 7,006,223 shares now+391,411
- Freestone Grove Partners LPexisting position · 358,043 shares now+281,990
- Walleye Capital LLCexisting position · 357,521 shares now+138,964
- Bridgewater Associates LPnew position · 133,112 shares now+133,112
Reductions
- Wellington Management Group LLPexisting position · 1,882,415 shares now-614,184
- Marshall Wace LLPexisting position · 833,146 shares now-303,120
- GAMCO Investors Incexisting position · 133,805 shares now-34
New positions and exits
New (2)
Exited (1)
- Point72 Asset Management LPwas $49m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 2 | $32m | n.a. | n.a. |
| Q3 2013 | 2 | $131m | n.a. | n.a. |
| Q4 2013 | 2 | $154m | n.a. | n.a. |
| Q1 2014 | 2 | $188m | n.a. | n.a. |
| Q2 2014 | 6 | $144m | n.a. | n.a. |
| Q3 2014 | 4 | $134m | n.a. | n.a. |
| Q4 2014 | 4 | $136m | n.a. | n.a. |
| Q1 2015 | 3 | $154m | n.a. | n.a. |
| Q2 2015 | 4 | $195m | n.a. | n.a. |
| Q3 2015 | 5 | $155m | n.a. | n.a. |
| Q4 2015 | 2 | $215m | n.a. | n.a. |
| Q1 2016 | 4 | $194m | n.a. | n.a. |
| Q2 2016 | 3 | $200m | n.a. | n.a. |
| Q3 2016 | 3 | $215m | n.a. | n.a. |
| Q4 2016 | 4 | $232m | n.a. | n.a. |
| Q1 2017 | 4 | $233m | n.a. | n.a. |
| Q2 2017 | 2 | $266m | n.a. | n.a. |
| Q3 2017 | 5 | $341m | n.a. | n.a. |
| Q4 2017 | 5 | $482m | n.a. | n.a. |
| Q1 2018 | 7 | $588m | n.a. | n.a. |
| Q2 2018 | 7 | $513m | n.a. | n.a. |
| Q3 2018 | 13 | $674m | n.a. | n.a. |
| Q4 2018 | 13 | $570m | n.a. | n.a. |
| Q1 2019 | 5 | $619m | n.a. | n.a. |
| Q2 2019 | 5 | $589m | n.a. | n.a. |
| Q3 2019 | 6 | $733m | n.a. | n.a. |
| Q4 2019 | 12 | $832m | n.a. | n.a. |
| Q1 2020 | 7 | $597m | n.a. | n.a. |
| Q2 2020 | 6 | $610m | n.a. | n.a. |
| Q3 2020 | 8 | $639m | n.a. | n.a. |
| Q4 2020 | 6 | $855m | n.a. | n.a. |
| Q1 2021 | 7 | $779m | n.a. | n.a. |
| Q2 2021 | 10 | $997m | n.a. | n.a. |
| Q3 2021 | 9 | $871m | n.a. | n.a. |
| Q4 2021 | 10 | $912m | n.a. | n.a. |
| Q1 2022 | 10 | $934m | n.a. | n.a. |
| Q2 2022 | 7 | $684m | n.a. | n.a. |
| Q3 2022 | 6 | $781m | n.a. | n.a. |
| Q4 2022 | 6 | $840m | n.a. | n.a. |
| Q1 2023 | 15 | $720m | n.a. | n.a. |
| Q2 2023 | 21 | $946m | n.a. | n.a. |
| Q3 2023 | 17 | $881m | n.a. | n.a. |
| Q4 2023 | 12 | $912m | 5 | 7 |
| Q1 2024 | 8 | $772m | 2 | 5 |
| Q2 2024 | 13 | $1.0bn | 6 | 6 |
| Q3 2024 | 12 | $868m | 5 | 6 |
| Q4 2024 | 14 | $1.4bn | 5 | 6 |
| Q1 2025 | 13 | $951m | 9 | 4 |
| Q2 2025 | 12 | $897m | 10 | 1 |
| Q3 2025 | 11 | $765m | 6 | 4 |
| Q4 2025 | 13 | $1.6bn | 12 | 20 |
| Q1 2026 | 14 | $1.6bn | 19 | 15 |
| Q2 2026 | 10 | $1.1bn | 14 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GMED and LLY →GMED and JNJ →GMED and VRTX →Choose a stock to compare with GMED →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GMED, latest filings →Back to the 13F Explorer →